Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMG 910 in Claudin 18.2–positive Gastric and Gastroesophageal Junction Adenocarcinoma
jRCT2031210242Phase 1Completed
- Sponsor
- Amgen
- Start
- Jun 2020
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
01
Overview
Phase 1, open-label trial of gresonitamab in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma (3 cohorts), sponsored by Amgen. Primary endpoints: Number of Participants Who Experienced a Dose-Limiting Toxicity (DLT) and Number of Participants Who Experienced a Treatment-emergent Adverse Event (TEAE). Started Jun 2020; status: completed.
02
Drugs
gresonitamab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on jRCT2031210242.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210242.